Following the recent article in the Lancet Oncology from Bisogno et al. reporting a randomized trial in which addition of metronomic maintenance therapy (MMT) with vinorelbine plus cyclophosphamide for children with high-risk rhabdomyosarcoma resulted in a significant increase in overall and event-free survival; Nicolas ANDRE, Yuval SHAKED and Nadège Corradini discuss in a "spotlight" piece published in Trends in Cancer about the mechanism of action that remains to be fully elucidated, (...)